Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Targeted Tissue Perfusion Versus Macrocirculatory-guided Standard Care in Patients With Septic Shock [TARTARE-2S]- A Multicentre Randomized Controlled Trial

NCT02579525 is registered in ClinicalTrials.gov with Helsinki University Central Hospital as lead sponsor.

NCT NCT02579525
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02579525 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Targeted Tissue Perfusion Versus Macrocirculatory-guided Standard Care in Patients With Septic Shock [TARTARE-2S]- A Multicentre Randomized Controlled Trial
Lead sponsor
Helsinki University Central Hospital
Phase
Not applicable
Overall status
Completed
Start date
May 31, 2016
Completion date
December 31, 2022
Enrollment
200 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

critical illness, shock; septic